Skip to main content

Table 1 Failed phase 3 trials on anti-amyloid therapy in AD since 2016

From: Clinical trials of new drugs for Alzheimer disease

Year

Drug

Mechanism of action

Participants

Main reasons for failure

Remarks

2016

Solanezumab

Monoclonal antibody

Mild AD

Lack of efficacy

 
 

Solanezumab

Monoclonal antibody

Prodromal AD

Strategic

 
 

Verubecestat

BACE inhibitor

Mild to moderate AD

Lack of efficacy

 

2018

Verubecestat

BACE inhibitor

Prodromal AD

Lack of efficacy

Worsens cognition

 

Atabecestat

BACE inhibitor

Preclinical AD

Toxicity

Worsens cognition

 

Lanabecestat

BACE inhibitor

Early AD

Lack of efficacy

Worsens cognition

 

Lanabecestat

BACE inhibitor

Mild AD

Lack of efficacy

Worsens cognition

2019

Aducanumab

Monoclonal antibody

Early AD

Lack of efficacy

 
 

CNP520

BACE inhibitor

Preclinical AD

Lack of efficacy

Worsens cognition